Новые возможности в коррекции микронутриентной недостаточности у больных со злокачественными новообразованиями

Новые возможности в коррекции микронутриентной недостаточности у больных со злокачественными новообразованиями

Автор: Джугашвили М., Покровский В.С., Снеговой А.В.

Журнал: Злокачественные опухоли @malignanttumors

Рубрика: Собственные исследования

Статья в выпуске: 2 (18), 2016 года.

Бесплатный доступ

Метаболизм опухолевых клеток при онкологических заболеваниях является причиной дефицита микронутриентов, особенно при распространенном опухолевом процессе. На сегодняшний день доказано, что у пациентов со злокачественными новообразованиями имеется дефицит отдельных аминокислот (глицин, аргинин, цистеин, аспарагин, лизин, метионин), витаминов (С, Е, D, группы B) и ряда микроэлементов (цинк, марганец, селен). К сожалению, проблеме микронутриентного дефицита и необходимости ее коррекции при онкологических заболеваниях не уделяется должного внимания. В современных исследованиях, в частности, проведенных у больных гепатоцеллюлярной карциномой в терминальной стадии, показано, что использование препаратов, влияющих на микронутриентный метаболизм (например, Онкоксин), позволяет увеличить аппетит, улучшить качество жизни, общее самочувствие и 2-месячную выживаемость. Таким образом, рациональная коррекция определенных микронутриентов может положительно влиять на общее состояние больных, результаты лечения и открывает новые перспективы в коррекции нарушений метаболизма у онкологических больных.

Еще

Злокачественные новообразования, микронутриентная недостаточность, онкоксин

Короткий адрес: https://sciup.org/140222650

IDR: 140222650   |   DOI: 10.18027/2224-5057-2016-2-Х-Х

Список литературы Новые возможности в коррекции микронутриентной недостаточности у больных со злокачественными новообразованиями

  • Снеговой А. В., Салтанов А. И., Манзюк Л. В., Сельчук В. Ю. Нутритивная недостаточность и методы ее лечения у онкологических больных//Практическая онкология. 2009. Т 10. № 1. с. 49-57
  • Hébuterne X., Lemarié E., Michallet M., de Montreuil C. B., Schneider S. M., Goldwasser F. Prevalence of malnutrition and current use of nutrition support in patients with cancer//J Parenter Enteral Nutr. 2014. 38(2). p. 196-204.
  • Снеговой A. B., Салтанов А.И, Манзюк Л. В.,Сельчук В. Ю. Нутритивная поддержка при проведении химиотерапии//РМЖ. 2008.T 16. № 27. c. 1818-1824.
  • Rolandelli R. H., Bankjhead R., Boullata J. I., Compher C. W. Clinical Nutrition. Enteral and Tube Feeding//Philadelphia. 2004. 672 p.
  • Гребёнкина Е. В., Гречканев Г. О. Применение нутритивной поддержки в комплексном лечении онкогинекологических больных//Нижегородский медицинский журнал. 2006. № 7. c. 72-76.
  • Хадышьян, Г. Г. Нутритивная поддержка онкологических больных пептидными смесями//Лечащий врач. 2005. N2. c. 14-15
  • Громова О. А., Ребров В. Г. Витамины и канцерогенез//РМЖ. 2007. № 9. c. 34-39. (Gromova O. A., Rebrov V. G. Vitamins and cancerogenesis/RMJ. 2007. N 9. p. 34-39)
  • Woo M., Park K., Nam J., Kim J. C. Clinical implications of matrix metalloproteinase-1,-3,-7,-9,-12, and plasminogen activator inhibitor-1 gene polymorphisms in colorectal cancer//J GastroenterolHepatol. 2007. 22(7). p. 1064-1070.
  • Finaud J., Lac G., Filaire E. Oxidative stress: relationship with exercise and training//Sports Med. 2006. 36(4). p. 327-358.
  • Bosetti C., Scotti L., Maso L. D., Talamini R., Montella M., Negri E., Ramazzotti V., Franceschi S., Vecchia C. L. Micronutrients and the risk of renal cell cancer: A case-control study from Italy//Int J Cancer. 2007. 15.120(4). p. 892-896.
  • Ames B. N. DNA damage from micronutrient deficiencies is likely to be a major cause of cancer//Mutat Res. 2001. 18. 475(1-2). p. 7-20.
  • Schernhammer E. S., Ogino S., Fuchs C. S. Folate and vitamin B6 intake and risk of colon cancer in relation to p53 expressio//Gastroenterology. 2008. 135(3). p. 770-780.
  • Schernhammer E., Wolpin B., Rifai N., Cochrane B., Manson J. A., Ma J., Giovannucci E., Thomson C., Stampfer M. J., Fuchs C. Plasma folate, vitamin B6, vitamin B12, and homocysteine and pancreatic cancer risk in four large cohorts//Cancer Res. 2007. 67(11). p. 5553-5560.
  • Pelucchi C., Galeone C., Talamini R., Negri E., Parpinel M., Franceschi S., Montella M., La Vecchia C. Dietary folate and risk of prostate cancer in Italy//Cancer Epidemiol Biomarkers Prev. 2005 14(4). p. 944-948.
  • Pathak S., Bajpai D., Banerjee A., Bhatla N., Jain S. K., Jayaram H. N., Singh N. Serum one-carbon metabolites and risk of cervical cancer//Nutr Cancer. 2014. 66(5). p. 818-824.
  • Alkan A., Mizrak D., Utkan G1. Lower folate levels in gastric cancer: is it a cause or a result?//World J Gastroenterol. 2015. 21(13). p. 4101-4102.
  • Whitehead V. M. Acquired and inherited disorders of cobalamin and folate in children//Br J Haematol. 2006.134(2).p.125-136.
  • Lee T. Y., Chiang E. P., Shih Y. T., Lane H. Y., Lin J. T., Wu C. Y. Lower serum folate is associated with development and invasiveness of gastric cancer//World J Gastroenterol. 2014. 20(32). p. 11313-11320.
  • Weinstein S. J., Stolzenberg-Solomon R. et al. Dietary factors of one-carbon metabolism and prostate cancer risk//Am J ClinNutr. 2006. 84(4). p.929-935.
  • Lajous M., Lazcano-Ponce E., Hernandez-Avila M. et al. Folate, vitamin B(6), and vitamin B(12) intake and the risk of breast cancer among Mexican women//Cancer Epidemiol Biomarkers Prev. 2006. 15(3). p. 443-448.
  • Gupta N., Saleem A., Kotz B., Osman S. et al. Carbogen and nicotinamide increase blood flow and 5-fluorouracil delivery but not 5-fluorouracil retention in colorectal cancer metastases in patients//Clin Cancer Res. 2006. 15;12(10). p. 3115-3123.
  • Fukagawa N. K., Galbraith R. A. Advancing age and other factors influencing the balance between amino acid requirements and toxicity//J Nutr. 2004. 134(6 Suppl). p. 1569-1574.
  • Vannini F., Kashfi K., Nath N. The dual role of iNOSin cancer//Redox Biol. 2015. 24;6. p. 334-343.
  • Cohen J., Chin W. D. Nutrition and sepsis//World Rev Nutr Diet. 2013. 105. p. 116-125.
  • Buijs N., Luttikhold J., Houdijk A. P., van Leeuwen P. A. The role of a disturbed arginine/NO metabolism in the onset of cancer cachexia: a working hypothesis//Curr Med Chem. 2012. 19(31). p. 5278-5286.
  • Zhong Z., Wheeler M. D., Li X., Froh M., Schemmer P., Yin M., Bunzendaul H., Bradford B., Lemasters J. J. L-Glycine: a novel antiinflammatory, immunomodulatory, and cytoprotective agent//CurrOpinClinNutrMetab Care. 2003. 6(2). p. 229-240.
  • Giger U., Büchler M., Farhadi J., Berger D., Hüsler J., Schneider H., Krähenbühl S., Krähenbühl L. Preoperative immunonutrition suppresses perioperative inflammatory response in patients with major abdominal surgery-a randomized controlled pilot study//Ann SurgOncol. 2007. 14(10). p. 2798-2806.
  • Ham D. J., Murphy K. T., Chee A., Lynch G. S.1, Koopman R. Glycine administration attenuates skeletal muscle wasting in a mouse model of cancer cachexia//ClinNutr. 2014. 33(3). p. 448-458.
  • Grotz M. R., Pape H. C., van Griensven M., Stalp M., Rohde F., Bock D., Krettek C. Glycine reduces the inflammatory response and organ damage in a two-hit sepsis model in rats//Shock. 2001. 16(2). p. 116-121.
  • McCarty M. F. Preclinical Studies Suggest Complex Nutraceutical Strategies May Have Potential for Preventing and Managing Sepsis//AlternTher Health Med. 2015. 21 Suppl 2. p. 56-67.
  • Miller G. W., Lock E. A., Schnellmann R. G. Strychnine and glycine protect renal proximal tubules from various nephrotoxicants and act in the late phase of necrotic cell injury//ToxicolApplPharmacol. 1994. 125(2). p. 192-197.
  • Zhong Z., Li X., Yamashina S., von Frankenberg M., Enomoto N., Ikejima K., Kolinsky M., Raleigh J. A., Thurman R. G. Cyclosporin A causes a hypermetabolic state and hypoxia in the liver: prevention by dietary glycine//J PharmacolExpTher. 2001. 299(3). p. 858-865.
  • Mauriz J. L., Matilla B., Culebras J. M., Gonzalez P., Gonzalez-Gallego J. Dietary glycine inhibits activation of nuclear factor kappa B and prevents liver injury in hemorrhagic shock in the rat//Free RadicBiol Med. 2001. 15.31(10). p. 1236-1244.
  • Rusyn I., Bradham C. A., Cohn L., Schoonhoven R., Swenberg J. A., Brenner D. A., Thurman R. G. Corn oil rapidly activates nuclear factor-kappaB in hepatic Kupffer cells by oxidant-dependent mechanisms//Carcinogenesis. 1999. 20(11). p. 2095-2100.
  • Rose M. L., Madren J., Bunzendahl H., Thurman R. G. Dietary glycine inhibits the growth of B16 melanoma tumors in mice//Carcinogenesis. 1999. 20(5). p. 793-798.
  • Diaz-Flores M., Cruz M., Duran-Reyes G., Munguia-Miranda C., Loza-Rodrfguez H., Pulido-Casas E., Torres-Ramirez N., Gaja-Rodriguez O., Kumate J., Baiza-Gutman L.A., Hernândez-Saavedra D. Oral supplementation with glycine reduces oxidative stress in patients with metabolic syndrome, improving their systolic blood pressure//Can J PhysiolPharmacol. 2013. 91(10). p. 855-860.
  • Nguyen D., Hsu J. W., Jahoor F., Sekhar R. V. Effect of increasing glutathione with cysteine and glycine supplementation on mitochondrial fuel oxidation, insulin sensitivity, and body composition in older HIV-infected patients//J ClinEndocrinolMetab. 2014. 99(1). p. 169-177.
  • Prasad A. S. Impact of the discovery of human zinc deficiency on health//J Trace Elem Med Biol. 2014. 28(4). p. 357-363.
  • Kitamura H., Morikawa H., Kamon H., Iguchi M., Hojyo S., Fukada T., Yamashita S., Kaisho T., Akira S., Murakami M., Hirano T. Toll-like receptor-mediated regulation of zinc homeostasis influences dendritic cell function//Nat Immunol. 2006. 7(9). p. 971-977.
  • Murakami M., Hirano T. Intracellular zinc homeostasis and zinc signaling//Cancer Sci. 2008. 99(8). p. 1515-1522.
  • Shankar A. H., Prasad A. S. Zinc and immune function: the biological basis of altered resistance to infection//Am J ClinNutr. 1998. 68. p. 447-463.
  • Haase H., Rink L. Signal transduction in monocytes: the role of zinc ions//Biometals. 2007. 20(3-4). p. 579-585.
  • Prasad A. S. Zinc in human health: effect of zinc on immune cells//Mol Med. 2008. 14(5-6). p. 353-357.
  • Bostanci Z., Mack R. P., Lee S., Soybel D. I., Kelleher S. L. Paradoxical zinc toxicity and oxidative stress in the mammary gland during marginal dietary zinc deficiency//ReprodToxicol. 2015. 54. p. 84-92.
  • Xie J., Owen T., Xia K., Singh A. V., Tou E., Li L., Arduini B., Li H., Wan L. Q., Callahan B., Wang C. Zinc inhibits Hedgehog autoprocessing: linking zinc deficiency with Hedgehog activation//J Biol Chem. 2015. 1; 290(18). p. 11591-11600.
  • Ciubotariu D., Ghiciuc C. M., Lupusoru C. E. Zinc involvement in opioid addiction and analgesia - should zinc supplementation be recommended for opioid-treated persons? // Subst Abuse Treat Prev Policy. 2015. 4; 10: 29.Sweeney J.D., Ziegler P., Pruet C., Spaulding M. B. Hyperzincuria and hypozincemia in patients treated with cisplatin // Cancer. 1989. 63(11). p. 2093-2095.
  • Prasad A. S. Zinc: mechanisms of host defense//JNutr. 2007. 137(5): 1345-9.
  • Yagi T., Asakawa A., Ueda H., Ikeda S., Miyawaki S., Inui A. The role of zinc in the treatment of taste disorders//Recent Pat Food Nutr Agric. 2013. 5(1). p. 44-51.
  • Friedman B. J., Freeland-Graves J.H., Bales C. W., Behmardi F., Shorey-Kutschke R.L., Willis R. A., Crosby J. B., Trickett P. C., Houston S. D. Manganese balance and clinical observations in young men fed a manganese-deficient diet//J Nutr. 1987. 117(1). p. 133-143.
  • Robbins D., Zhao Y. Manganese superoxide dismutase in cancer prevention//Antioxid Redox Signal. 2014. 20(10). p. 1628-1645.
  • Konzack A., Jakupovic M., Kubaichuk K., Görlach A., Dombrowski F., Miinalainen I., Sormunen R., Kietzmann T. Mitochondrial dysfunction due to lack of manganese superoxide dismutase promotes hepatocarcinogenesis//Antioxid Redox Signal. 2015. .
  • Towheed T. E., Maxwell L., Anastassiades T. P., Shea B., Houpt J., Robinson V., Hochberg M. C., Wells G. Glucosamine therapy for treating osteoarthritis//Cochrane Database Syst Rev. 2005. (2). CD002946.
  • Bell G. A., Kantor E. D., Lampe J. W., Shen D. D., White E. Use of glucosamine and chondroitin in relation to mortality//Eur J Epidemiol. 2012. 27(8). p. 593-603.
  • Kantor E. D., Lampe J. W., Navarro S. L., Song X., Milne G. L., White E. Associations between glucosamine and chondroitin supplement use and biomarkers of systemic inflammation//J Altern Complement Med. 2014. 20(6). p. 479-485.
  • Bak Y. K., Lampe J. W., Sung M. K. Effects of dietary supplementation of glucosamine sulfate on intestinal inflammation in a mouse model of experimental colitis//J Gastroenterol Hepatol. 2014. 29(5). p. 957-963.
  • Koga K., Kawashima S., Shibata N., Takada K. Novel formulations of a liver protection drug glycyrrhizin//YakugakuZasshi. 2007. 127(7). p. 1103-1114.
  • Cichon T., Smolarczyk R., Matuszczak S., Barczyk M., Jarosz M., Szala S. D-K6L 9 peptide combination with IL-12 inhibits the recurrence of tumors in mice//Arch ImmunolTherExp (Warsz). 2014. 62(4). p. 341-351.
  • Huang R. Y., Chu Y. L., Jiang Z. B., Chen X. M., Zhang X., Zeng X. Glycyrrhizin suppresses lung adenocarcinoma cell growth through inhibition of thromboxane synthase//Cell PhysiolBiochem. 2014. 33(2). p. 375-388.
  • Li S., Zhu J. H., Cao L. P., Sun Q., Liu H. D., Li W. D., Li J. S., Hang C. H. Growth inhibitory in vitro effects of glycyrrhizic acid in U251 glioblastoma cell line//Neurol Sci. 2014. 35(7). p. 1115-1120.
  • Khan R., Khan A. Q., Lateef A., Rehman M. U., Tahir M., Ali F., Hamiza O. O., Sultana S. Glycyrrhizic acid suppresses the development of precancerous lesions via regulating the hyperproliferation, inflammation, angiogenesis and apoptosis in the colon of Wistar rats//PLoS One. 2013. 8(2). p. 56020.
  • Chueh F. S., Hsiao Y. T., Chang S. J., Wu P. P., Yang J. S., Lin J. J., Chung J. G., Lai T. Y. Glycyrrhizic acid induces apoptosis in WEHI-3 mouse leukemia cells through the caspase-and mitochondria-dependent pathways//Oncol Rep. 2012. 28(6). p. 2069-2076.
  • He S. Q., Gao M., Fu Y. F., Zhang Y. N. Glycyrrhizic acid inhibits leukemia cell growth and migration via blocking AKT/mTOR/STAT3 signaling//Int J Clin Exp Pathol. 2015. 8(5). p. 5175-5181.
  • Veldt B. J., Hansen B. E., Ikeda K., Verhey E., Suzuki H., Schalm S. W. Long-term clinical outcome and effect of glycyrrhizin in 1093 chronic hepatitis C patients with nonresponse or relapse to interferon//Scand J Gastroenterol. 2006. 41(9). p. 1087-1094.
  • Ikeda K., Kawamura Y., Kobayashi M., Fukushima T., Sezaki H., Hosaka T., Akuta N., Saitoh S., Suzuki F., Suzuki Y., Arase Y., Kumada H. Prevention of disease progression with anti-inflammatory therapy in patients with HCV-related cirrhosis: a Markov model//Oncology. 2014. 86(5-6). p. 295-302.
  • Manns M. P., Wedemeyer H., Singer A., Khomutjanskaja N., Dienes H. P., Roskams T., Goldin R., Hehnke U., Inoue H.; European SNMC Study Group. Glycyrrhizin in patients who failed previous interferon alpha-based therapies: biochemical and histological effects after 52 weeks//J Viral Hepat. 2012. 19(8). p. 537-546.
  • Yasui S., Fujiwara K., Tawada A., Fukuda Y., Nakano M., Yokosuka O. Efficacy of intravenous glycyrrhizin in the early stage of acute onset autoimmune hepatitis//Dig Dis Sci. 2011. 56(12). p. 3638-3647.
  • Cao Z. X., Zhao Z. F., Zhao X. F. Effect of compound glycyrrhizin injection on liver function and cellular immunity of children with infectious mononucleosis complicated liver impairment//Chin J Integr Med. 2006. 12(4). p. 268-272.
  • Yan Y., Mo Y., Zhang D. Magnesium isoglycyrrhizinate prevention of chemotherapy-induced liver damage during initial treatment of patients with gastrointestinal tumors//ZhonghuaGanZang Bing ZaZhi. 2015. 23(3). p. 204-208.
  • Moses M. A., Henry E. C., Ricke W. A., Gasiewicz T. A. The heat shock protein 90 inhibitor, (-)-epigallocatechin gallate, has anticancer activity in a novel human prostate cancer progression model//Cancer Prev Res (Phila). 2015. 8(3). p. 249-257.
  • Shanafelt T. D., Call T. G., Zent C. S., LaPlant B., Bowen D. A., Roos M., Secreto C. R., Ghosh A. K., Kabat B. F., Lee M. J., Yang C. S., Jelinek D. F., Erlichman C., Kay N. E. Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia//J ClinOncol. 2009. 27(23). p. 3808-3814.
  • D'Arena G., Simeon V., De Martino L., Statuto T., D'Auria F., Volpe S., Deaglio S., Maidecchi A., Mattoli L., Mercati V., Musto P., De Feo V. Regulatory T-cell modulation by green tea in chronic lymphocytic leukemia//Int J ImmunopatholPharmacol. 2013. 26(1). p. 117-125.
  • Shanafelt T. D., Call T. G., Zent C. S., Leis J. F., LaPlant B., Bowen D. A., Roos M., Laumann K., Ghosh A. K., Lesnick C., Lee M. J., Yang C. S., Jelinek D. F., Erlichman C., Kay N. E. Phase 2 trial of daily, oral Polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia//Cancer. 2013. 119(2). p. 363-370.
  • Hoensch H., Groh B., Edler L., Kirch W. Prospective cohort comparison of flavonoid treatment in patients with resected colorectal cancer to prevent recurrence//World J Gastroenterol. 2008. 14(14). p. 2187-2193.
  • Zhao H., Zhu W., Xie P., Li H., Zhang X., Sun X., Yu J., Xing L. A phase I study of concurrent chemotherapy and thoracic radiotherapy with oral epigallocatechin-3-gallate protection in patients with locally advanced stage III non-small-cell lung cancer//RadiotherOncol. 2014. 110(1). p. 132-136.
  • Zhao H., Xie P., Li X., Zhu W., Sun X., Sun X., Chen X., Xing L., Yu J. A prospective phase II trial of EGCG in treatment of acute radiation-induced esophagitis for stage III lung cancer//RadiotherOncol. 2015. 114(3). p. 351-356.
  • Yoon J. Y., Kwon H. H., Min S. U., Thiboutot D. M., Suh D. H. Epigallocatechin-3-gallate improves acne in humans by modulating intracellular molecular targets and inhibiting P. acnes//J Invest Dermatol. 2013. 133(2). p. 429-440.
  • Dryden G. W., Lam A., Beatty K., Qazzaz H. H., McClain C.J. A pilot study to evaluate the safety and efficacy of an oral dose of (-)-epigallocatechin-3-gallate-rich polyphenon E in patients with mild to moderate ulcerative colitis//Inflamm Bowel Dis. 2013. 19(9) p. 1904-1912.
  • Liu M., Xu Y. F., Feng Y., Yang F. Q., Luo J., Zhai W., Che J. P., Wang G. C., Zheng J. H. Epigallocatechin gallate attenuates interstitial cystitis in human bladder urothelium cells by modulating purinergic receptors//J Surg Res. 2013. 183(1). p. 397-404.
  • Dominiak K., McKinney J., Heilbrun L. K., Sarkar F. H. Critical need for clinical trials: an example of a pilot human intervention trial of a mixture of natural agents protecting lymphocytes against TNF-alpha induced activation of NF-kappaB//Pharm Res. 2010. 27(6). p. 1061-1065.
  • Marquez J., Mena J., Hernandez I., Vilar E., Benedicto A., Arteta B., Sanz E., Olaso E. Ocoxin-Viusid Slows Down Tumor Progression Of Colorrectal Cancer Metastasis Development To The Liver In A Murine Model//ILCA Annual Conference 2015. Book of abstracts. p. 58.
  • Arriazu E., de Galarreta M. R., de Obanos P., Iraburu M. Ocoxin+Viusid induces apoptosis of hepatoma cells and potentiates the effect of sorafenib on hepatoma cells//Journal of Hepatology. 2012. Vol. 56.Suppl 2. p. 135-136.
  • Hernandez-Garcia S., Gonzalez V., Sanz E., Pandiella A. Effect of Oncoxin Oral Solution in HER2-Overexpressing Breast Cancer//Nutr Cancer. 2015. 67(7). p. 1159-1169.
  • Al-Mahtab M., Akbar S., Khan M., Rahman S. Increased survival of patients with end-stage hepatocellular carcinoma due to intake of ONCOXIN(®), a dietary supplement//Indian J Cancer. 2015. 52(3). p. 443-446.
Еще
Статья научная
SciUp 2024 © 2024 ©